Eli Lilly reports EPS in-line, beats on revs; lowers FY18 EPS and revenue guidance (120.43)
- Reports Q4 (Dec) earnings of $1.33 per share, excluding non-recurring items, in-line with the S&P Capital IQ Consensus of $1.33; revenues rose 4.5% year/year to $6.44 bln vs the $6.28 bln S&P Capital IQ Consensus.
- Co issues lowered guidance for FY19, sees EPS of $5.55-5.65 from $5.90-6.10, excluding non-recurring items, vs. $5.69 S&P Capital IQ Consensus; sees FY19 revs of $25.1-25.6 bln from $25.3-25.8 bln vs. $25.1 bln S&P Capital IQ Consensus.
- Guidance lowered primarily due to the anticipated impacts of both the pending acquisition of Loxo Oncology and the negative Phase 3 confirmatory trial for Lartruvo, partially offset by a more favorable underlying business outlook. Revenue growth is still expected to be driven by volume from newer medicines including Trulicity, Taltz, Basaglar, Jardiance, Verzenio, Cyramza and Olumiant. Revenue growth is also expected to benefit from the recent launch of Emgality and the anticipated inclusion of Vitrakvi, and could benefit from the potential approval and launch of other medicines is 2019